France's Dynacure Gets VC Backing To Progress Antisense Candidate For Myopathy

Strasbourg, France-based Dynacure may only have been set up two years ago, but in some ways it is a "mature start up", and has been able to raise a hefty €47m ($55m) from VCs and institutional investors in its first substantial financing round to support the move of its lead product candidate, Dyn101, into the clinic for the rare and often fatal muscle disease, centronuclear myopathy (CNM).

Stephane van Rooijen, CEO